Rapamycin-induced glucose intolerance: Hunger or starvation diabetes

Cell Cycle

Volumn 10, Issue 24, 2011, Pages 4217-4224

  Blagosklonny, Mikhail V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Hunger; Insulin; mTOR; Starvation

Indexed keywords

INSULIN; KETONE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; RAPAMYCIN;

ATHEROSCLEROSIS; BREAST CANCER; CALORIC RESTRICTION; DIABETES MELLITUS; DIABETIC DIET; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; EXERCISE; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW;

EID: 84055190702     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.24.18595     Document Type: Review

References (149)

1. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-12; PMID:19543266; http://dx.doi.org/10.1038/nature08155.
2. Chen C, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2009; 2:75; PMID:19934433; http://dx.doi.org/10.1126/scisignal.2000559.
3. Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. Temsirolimus, an mTOR inhibitor, enhances antitumour effects of heat shock protein cancer vaccines. Br J Cancer 2011; 104:643-52; PMID:21285988; http://dx.doi.org/10.1038/bjc.2011. 15.
4. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther 2008; 7:1520-4; PMID:18769112; http://dx.doi.org/10.4161/cbt.7.10.6663.
5. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317-23; PMID:15800227; http://dx.doi.org/10.1056/NEJMoa042831.
6. Blankenship JR, Steinbach WJ, Perfect JR, Heitman J. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investig Drugs 2003; 4:192-9; PMID:12669381.
7. Krakauer T, Buckley M, Issaq HJ, Fox SD. Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo. Antimicrob Agents Chemother 2010; 54:1125-31; PMID:20086156; http://dx.doi.org/10.1128/AAC.01015-09.
8. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28:721-6; PMID:1102508.
9. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253:905-9; PMID:1715094; http://dx.doi.org/10.1126/science.1715094.
10. Powers RW, 3rd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological lifespan in yeast by decreased TOR pathway signaling. Genes Dev 2006; 20:174-84; PMID:16418483; http://dx.doi.org/10.1101/gad. 1381406.
11. Pan Y, Shadel GS. Extension of chronological lifespan by reduced TOR signaling requires downregulation of Sch9p and involves increased mitochondrial OXPHOS complex density. Aging 2009; 1:131-5; PMID:20157595.
12. Blagosklonny MV, Hall MN. Growth and aging: a common molecular mechanism. Aging 2009; 1:357-62; PMID:20157523.
13. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7:3355-61; PMID:18948731; http://dx.doi.org/10.4161/cc.7.21.6919.
14. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell Cycle 2009; 8:4112-8; PMID:19946210; http://dx.doi.org/10.4161/cc.8.24.10215.
15. Demidenko ZN, Blagosklonny MV. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging 2009; 1:1008-16; PMID:20157583.
16. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8:1888-95; PMID:19471117; http://dx.doi.org/10.4161/cc.8.12.8606.
17. Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging 2010; 2:924-35; PMID:21212465.
18. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107:9660-4; PMID:20457898; http://dx.doi.org/10.1073/pnas.1002298107.
19. Romanov VS, Abramova MV, Svetlikova SB, Bykova TV, Zubova SG, Aksenov ND, et al. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. Cell Cycle 2010; 9:3945-55; PMID:20935470; http://dx.doi.org/10.4161/cc.9.19.13160.
20. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17:596-603; PMID:16226444; http://dx.doi.org/10.1016/ j.ceb.2005.09.009.
21. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005; 16:29-37; PMID:15659337; http://dx.doi.org/10.1016/j.semcdb. 2004.11.005.
22. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84; PMID:16469695; http://dx.doi.org/10.1016/j. cell.2006.01.016.
23. Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy? Aging 2009; 1:586-97; PMID:20157541.
24. Glazer HP, Osipov RM, Clements RT, Sellke FW, Bianchi C. Hypercholesterolemia is associated with hyperactive cardiac mTORC1 and mTORC2 signaling. Cell Cycle 2009; 8:1738-46; PMID:19395857; http://dx.doi.org/10.4161/ cc.8.11.8619.
25. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010; 11:453-65; PMID:20519118; http://dx.doi.org/10.1016/j. cmet.2010.05.001.
26. Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle 2009; 8:1883-7; PMID:19448395; http://dx.doi.org/10.4161/cc.8.12.8815.
27. Blagosklonny MV. Cell cycle arrest is not senescence. Aging 2011; 3:94-101; PMID:21297220.
28. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006; 5:2087-102; PMID:17012837; http://dx.doi.org/10.4161/cc.5.18.3288.
29. Tsang CK, Qi H, Liu LF, Zheng XFS. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007; 12:112-24; PMID:17275731; http://dx.doi.org/10.1016/j.drudis.2006.12.008.
30. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging 2009; 1:281-8; PMID:20157517.
31. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35; PMID:21157483; http://dx.doi.org/10.1038/nrm3025.
32. Blagosklonny MV. Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging"hypothesis. Aging 2010; 2:177-82; PMID:20404395.
33. Blagosklonny MV. Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives. Aging 2010; 2:265-73; PMID:20519781.
34. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature 2009; 460:392-5; PMID:19587680.
35. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 2010; 176:2092-7; PMID:20363920; http://dx.doi.org/10.2353/ajpath.2010. 091050.
36. Moskalev AA, Shaposhnikov MV. Pharmacological inhibition of Phosphoinositide 3 and TOR kinases improves survival of Drosophila melanogaster. Rejuvenation Res 2010; 13:246-7; PMID:20017609; http://dx.doi.org/10.1089/rej. 2009.0903.
37. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, et al. Mechanisms of lifespan extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010; 11:35-46; PMID:20074526; http://dx.doi.org/10. 1016/j.cmet.2009.11.010.
38. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011; 332:1317-22; PMID:21659604; http://dx.doi.org/10.1126/science.1199498.
39. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011; 332:1322-6; PMID:21659605; http://dx.doi.org/10.1126/science.1199484.
40. Mordier S, Iynedjian PB. Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes. Biochem Biophys Res Commun 2007; 362:206-11; PMID:17698034; http://dx.doi.org/10.1016/j. bbrc.2007.08.004.
41. Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, et al. A phosphatidylinositol-3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 2001; 98:4640-5; PMID:11287630; http://dx.doi.org/10.1073/pnas.051042298.
42. Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 2001; 276:38052-60; PMID:11498541.
43. Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, et al. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 2005; 54:2674-84; PMID:16123357; http://dx.doi.org/10.2337/diabetes.54.9.2674.
44. Tremblay F, Bržl Ž, Hee S, Um S, Li Y, Masuda K, et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 2007; 104:14056-61; PMID:17709744; http://dx.doi.org/10.1073/pnas.0706517104.
45. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol-3-kinase/ Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006; 26:63-76; PMID:16354680; http://dx.doi.org/10.1128/MCB.26.1.63-76.2006.
46. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance and cell survival deficiencies. Curr Biol 2004; 14:1650-6; PMID:15380067; http://dx.doi.org/10.1016/j.cub.2004.08.026.
47. Cao Y, Kamioka Y, Yokoi N, Kobayashi T, Hino O, Onodera M, et al. Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway. J Biol Chem 2006; 281:40242-51; PMID:17077083; http://dx.doi.org/10.1074/jbc.M608116200.
48. Robinson KA, Buse MG. Mechanisms of high-glucose/insulin-mediated desensitization of acute insulin-stimulated glucose transport and Akt activation. Am J Physiol Endocrinol Metab 2008; 294:870-81; PMID:18303120; http://dx.doi.org/10.1152/ajpendo.00644.2007.
49. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway downregulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000; 14:783-94; PMID:10847581; http://dx.doi.org/10.1210/me.14.6.783.
50. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431:200-5; PMID:15306821; http://dx.doi.org/ 10.1038/nature02866.
51. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y, et al. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 2000; 408:994-7; PMID:11140689; http://dx.doi.org/10.1038/35050135.
52. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian lifespan. Science 2009; 326:140-4; PMID:19797661; http://dx.doi.org/10.1126/science.1177221.
53. Bartke A. Insulin and aging. Cell Cycle 2008; 7:3338-43; PMID:18948730; http://dx.doi.org/10.4161/cc.7.21.7012.
54. Masternak MM, Panici JA, Bonkowski MS, Hughes LF, Bartke A. Insulin sensitivity as a key mediator of growth hormone actions on longevity. J Gerontol A Biol Sci Med Sci 2009; 64:516-21; PMID:19304940; http://dx.doi.org/10.1093/ gerona/glp024.
55. Paolisso G, Gambardella A, Ammendola S, D'Amore A, Balbi V, Varricchio M, et al. Glucose tolerance and insulin action in healty centenarians. Am J Physiol 1996; 270:890-4; PMID:8967479.
56. Klöting N, Bluher M. Extended longevity and insulin signaling in adipose tissue. Exp Gerontol 2005; 40:878-83; PMID:16125891; http://dx.doi.org/10.1016/j.exger.2005.07.004.
57. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005; 146:1473-81; PMID:15604215; http://dx.doi.org/10.1210/en.2004-0921.
58. Barbour LA, McCurdy CE, Hernandez TL, Friedman JE. Chronically increased S6K1 is associated with impaired IRS1 signaling in skeletal muscle of GDM women with impaired glucose tolerance post-partum. J Clin Endocrinol Metab 2011; 96:1431-41; PMID:21289241; http://dx.doi.org/10.1210/jc.2010-116.
59. Liu Z, Wu Y, Nicklas EW, Jahn LA, Price WJ, Barrett EJ. Unlike insulin, amino acids stimulate p70S6K but not GSK-3 or glycogen synthase in human skeletal muscle. Am J Physiol Endocrinol Metab 2004; 286:523-8; PMID:14656717; http://dx.doi.org/10.1152/ajpendo.00146.2003.
60. Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P, et al. The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 2007; 56:1600-7; PMID:17329620; http://dx.doi.org/10. 2337/db06-1016.
61. Ueno M, Carvalheira JB, Tambascia RC, Bezerra RM, Amaral ME, Carneiro EM, et al. Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 2005; 48:506-18; PMID:15692808; http://dx.doi.org/10.1007/s00125-004-1662-6.
62. Chiasson JL, Rabasa-Lhoret R. Prevention of type 2 diabetes: insulin resistance and beta-cell function. Diabetes 2004; 53:34-8; PMID:15561919; http://dx.doi.org/10.2337/diabetes.53.suppl-3.S34.
63. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365:1333-46; PMID:15823385; http://dx.doi.org/10.1016/S0140-6736(05)61032-X.
64. Rhodes CJ. Type 2 diabetes-a matter of betacell life and death? Science 2005; 307:380-4; PMID:15662003; http://dx.doi.org/10.1126/science.1104345.
65. DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011; 34:202-9; PMID:21525456; http://dx.doi.org/10.2337/dc11-s221.
66. Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991; 14:802-23; PMID:1959474; http://dx.doi.org/10.2337/diacare.14.9.802.
67. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994; 17:30-6; PMID:8112186; http://dx.doi.org/10.2337/diacare.17.1.30.
68. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007; 292:617-27; PMID:17018841; http://dx.doi.org/10.1152/ajprenal.00278.2006.
69. Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt and mammalian target of rapamycin in mammary carcinomas, mammary gland and liver. Cancer Res 2008; 68:5492-9; PMID:18593953; http://dx.doi.org/10.1158/0008-5472.CAN-07-6721.
70. Estep PW, 3rd, Warner JB, Bulyk ML. Short-term calorie restriction in male mice feminizes gene expression and alters key regulators of conserved aging regulatory pathways. PLoS ONE 2009; 4:5242; PMID:19370158; http://dx.doi.org/ 10.1371/journal.pone.0005242.
71. Glynn EL, Lujan HL, Kramer VJ, Drummond MJ, DiCarlo SE, Rasmussen BB. A chronic increase in physical activity inhibits fed-state mTOR/S6K1 signaling and reduces IRS-1 serine phosphorylation in rat skeletal muscle. Appl Physiol Nutr Metab 2008; 33:93-101; PMID:18347658; http://dx.doi.org/10.1139/H07-149.
72. Girach A, Vignati L. Diabetic microvascular complications - can the presence of one predict the development of another. J Diabetes Complications 2006; 20:228-37; PMID:16798474; http://dx.doi.org/10.1016/j.jdiacomp.2006.03. 001.
73. Chiarelli F, Giannini C, Di Marzio D, Mohn A. Treating diabetic retinopathy by tackling growth factor pathways. Curr Opin Investig Drugs 2005; 6:395-409; PMID:15898347.
74. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376:419-30; PMID:20594588; http://dx.doi.org/10.1016/S0140-6736(10)60576-4.
75. Lim LS, Liew G, Cheung N, Mitchell P, Wong TY. Mixed messages on systemic therapies for diabetic retinopathy. Lancet 2010; 376:1461; PMID:21036265; http://dx.doi.org/10.1016/S0140-6736(10)61984-8.
76. Henricsson M, Janzon L, Groop L. Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM. Diabetes Care 1995; 18:1571-6; PMID:8722053; http://dx.doi.org/10.2337/ diacare.18.12.1571.
77. Cohen JA, Jeffers BW, Faldut D, Marcoux M, Schrier RW. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Muscle Nerve 1998; 21:72-80; PMID:9427226; http://dx.doi.org/10.1002/(SICI)1097-4598(199801)21:1〈72:: AID-MUS10〉3.0.CO;2-2.
78. Funatsu H, Yamashita H, Ohashi Y, Ishigaki T. Effect of rapid glycemic control on progression of diabetic retinopathy. Jpn J Ophthalmol 1992; 36:356-67; PMID:1464975.
79. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010; 67:534-41; PMID:20437589; http://dx.doi.org/10.1002/ana.21952.
80. Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity and lifestyle study. J Clin Oncol 2011; 29:47-53; PMID:21115859; http://dx.doi.org/10.1200/JCO.2010.28.4752.
81. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Tyndyk ML, et al. Central and peripheral effects of insulin/IGF-1 signaling in aging and cancer: antidiabetic drugs as geroprotectors and anticarcinogens. Ann N Y Acad Sci 2005; 1057:220-34; PMID:16399897; http://dx.doi.org/10.1196/annals. 1356.017.
82. Anisimov VN. Metformin for aging and cancer prevention. Aging 2010; 2:760-74; PMID:21084729.
83. Blagosklonny MV. Insulin resistance, complications, diabetes and mTOR: Surprising sequence of events and therapeutic opportunities. Aging 2011; 3; In press.
84. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815-9; PMID:1516497; http://dx.doi.org/10.2337/diacare.15.7.815.
85. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011; 34:145-50; PMID:20978099; http://dx.doi.org/10.2337/dc10-1206.
86. Ellis JD, Zvandasara T, Leese G, McAlpine R, Macewen CJ, Baines PS, et al. Clues to duration of undiagnosed disease from retinopathy and maculopathy at diagnosis in type 2 diabetes: a cross-sectional study. Br J Ophthalmol 2011; 95:1229-33; PMID:21183519; http://dx.doi.org/10.1136/bjo.2010.196204.
87. Singleton JR, Smith AG. Therapy insight: neurological complications of prediabetes. Nat Clin Pract Neurol 2006; 2:276-82; PMID:16932564; http://dx.doi.org/10.1038/ncpneuro0172.
88. Singleton JR, Smith AG. Neuropathy associated with prediabetes: what is new in 2007? Curr Diab Rep 2007; 7:420-4; PMID:18255003; http://dx.doi.org/10. 1007/s11892-007-0070-y.
89. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist 2008; 14:23-9; PMID:18195653; http://dx.doi.org/10.1097/NRL. 0b013e31815a3956.
90. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52:2867-73; PMID:14633845; http://dx.doi.org/10.2337/diabetes.52.12.2867.
91. Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005; 1:100-10; PMID:16929378; http://dx.doi.org/10.1038/ ncpendmet0046.
92. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007; 24:137-44; PMID:17257275; http://dx.doi.org/10.1111/j.1464-5491.2007.02043.x.
93. Meigs JB, D'Agostino RBS, Nathan DM, Rifai N, Wilson PW. Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care 2002; 25:977-83; PMID:12032102; http://dx.doi.org/10.2337/diacare. 25.6.977.
94. Wilson PW, Kannel WB. Obesity, diabetes and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol 2002; 11:119-23; PMID:11872970; http://dx.doi.org/10.1111/j.1076-7460.2002.00998.x.
95. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343:4169; PMID:21791495; http://dx.doi.org/10.1136/bmj.d4169.
96. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17:1395-404; PMID:16597691; http://dx.doi.org/10.1681/ASN.2005050549.
97. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 2006; 340:296-301; PMID:16364254; http://dx.doi.org/10.1016/j.bbrc.2005.12.012.
98. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007; 27:495-502; PMID:17671379; http://dx.doi.org/10.1159/000106782.
99. Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K, Hugo C. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation 2009; 87:1290-9; PMID:19424027; http://dx.doi.org/10. 1097/TP.0b013e3181a192bd.
100. Zafar I, Belibi FA, He Z, Edelstein CL. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 2009; 24:2349-53; PMID:19321761; http://dx.doi.org/10.1093/ndt/ gfp129.
101. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16:2063-72; PMID:15917339; http://dx.doi.org/10.1681/ASN.2004030180.
102. Krüger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Boger CA, et al. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. Transplant Proc 2007; 39:518-21; PMID:17362772; http://dx.doi.org/10.1016/j.transproceed.2006. 12.004.
103. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004; 10:964-72; PMID:15623986.
104. Nussenblatt RB, Byrnes G, Sen HN, Yeh S, Faia L, Meyerle C, et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010; 30:1579-87; PMID:20847709; http://dx.doi.org/10.1097/IAE.0b013e3181e7978e.
105. Elloso MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3:562-9; PMID:12752312; http://dx.doi.org/10.1034/j.1600-6143.2003.00094.x.
106. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005; 46:481-6; PMID:16160601; http://dx.doi.org/10.1097/01.fjc.0000177985.14305.15.
107. Mueller MA, Beutner F, Teupser d, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimis in LDLR-/- mice despite hypercholesterolemia. Atherosclerosis 2008; 198:39-48; PMID:17980369; http://dx.doi.org/10.1016/j.atherosclerosis.2007.09.019.
108. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, et al. Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 2006; 47:1522-9; PMID:16630986; http://dx.doi.org/10.1016/j.jacc.2005.12.052.
109. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer 2010; 17:941-51; PMID:20801951; http://dx.doi.org/10.1677/ERC-10-0091.
110. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29:351-66; PMID:18048763; http://dx.doi.org/10. 1210/er.2007-0023.
111. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller- Jemelka HI, Spinas GA, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851-60; PMID:12235117.
112. Bachar E, Ariav Y, Ketzinel-Gilad M, Cerasi E, Kaiser N, Leibowitz G. Glucose amplifies fatty acid-induced endoplasmic reticulum stress in pancreatic beta-cells via activation of mTORC1. PLoS ONE 2009; 4:4954; PMID:19305497; http://dx.doi.org/10.1371/journal.pone.0004954.
113. Elghazi L, Balcazar N, Blandino-Rosano M, Cras-Meneur C, Fatrai S, Gould AP, et al. Decreased IRS signaling impairs beta-cell cycle progression and survival in transgenic mice overexpressing S6K in betacells. Diabetes 2010; 59:2390-9; PMID:20622167; http://dx.doi.org/10.2337/db09-0851.
114. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback downregulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem 2005; 280:2282-93; PMID:15537654; http://dx.doi.org/10.1074/jbc.M412179200.
115. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008; 57:945-57; PMID:18174523; http://dx.doi.org/10.2337/db07-0922.
116. Leibowitz G, Cerasi E, Ketzinel-Gilad M. The role of mTOR in the adaptation and failure of beta-cells in type 2 diabetes. Diabetes Obes Metab 2008; 10:157-69; PMID:18834443; http://dx.doi.org/10.1111/j.1463-326.2008.00952. x.
117. Rachdi L, Balcazar N, Osorio-Duque F, Elghazi L, Weiss A, Gould A, et al. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. Proc Natl Acad Sci USA 2008; 105:9250-5; PMID:18587048; http://dx.doi.org/10.1073/pnas.0803047105.
118. Shigeyama Y, Kobayashi T, Kido Y, Hashimoto N, Asahara S, Matsuda T, et al. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol 2008; 28:2971-9; PMID:18316403; http://dx.doi.org/10.1128/MCB.01695-07.
119. Chang GR, Wu YY, Chiu YS, Chen WY, Liao JW, Hsu HM, et al. Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Basic Clin Pharmacol Toxicol 2009; 105:188-98; PMID:19496779; http://dx.doi.org/10.1111/j.1742-7843.2009.00427.x.
120. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010; 59:1338-48; PMID:20299475; http://dx.doi.org/10. 2337/db09-1324.
121. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16:3128-35; PMID:16107580; http://dx.doi.org/10.1681/ASN.2005050487.
122. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant Proc 2009; 41:31-8; PMID:19651294; http://dx.doi.org/10.1016/j.transproceed.2009.06.159.
123. Lundbaek K. Metabolic abnormalities in starvation diabetes. Yale J Biol Med 1948; 20:533-44; PMID:18872320.
124. Randle PJ, Kerbey AL, Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metab Rev 1988; 4:623-38; PMID:3069395; http://dx.doi.org/10.1002/dmr.5610040702.
125. Fery F, d'Attellis NP, Balasse EO. Mechanisms of starvation diabetes: a study with double tracer and indirect calorimetry. Am J Physiol 1990; 259:770-7; PMID:2260646.
126. Huang B, Wu P, Popov KM, Harris RA. Starvation and diabetes reduce the amount of pyruvate dehydrogenase phosphatase in rat heart and kidney. Diabetes 2003; 52:1371-6; PMID:12765946; http://dx.doi.org/10.2337/diabetes.52.6.1371.
127. Dieterle P, Bachl I, Bachl G, Henner J, Frommeld D, Minkus P, et al. Muscle metabolism during exercise in diabetics and in obese during starvation. Horm Metab Res 1978; 10:263-8; PMID:680626; http://dx.doi.org/10.1055/s-0028- 1093411.
128. Duska F, Andel M, Kubena A, Macdonald IA. Effects of acute starvation on insulin resistance in obese patients with and without type 2 diabetes mellitus. Clin Nutr 2005; 24:1056-64; PMID:16185788; http://dx.doi.org/10.1016/j.clnu. 2005.08.008.
129. Zawalich WS, Dye ES, Pagliara AS, Rognstad R, Matschinsky FM. Starvation diabetes in the rat: onset, recovery and specificity of reduced responsiveness of pancreatic beta-cells. Endocrinology 1979; 104:1344-51; PMID:374069; http://dx.doi.org/10.1210/endo-104-5-1344.
130. Joost HG, Beckmann J. On the relation of glucose and insulin secretion in the fasting state. Metabolism 1980; 29:23-7; PMID:6986011; http://dx.doi.org/ 10.1016/0026-0495(80)90093-1.
131. Hahn HJ, Gottschling HD. Insulin secretion reactivation of pancreatic islets from starved rats in vitro. Acta Biol Med Ger 1977; 36:1423-7; PMID:356495.
132. Zawalich WS, Zawalich KC. Glucose-induced insulin secretion from islets of fasted rats: modulation by alternate fuel and neurohumoral agonists. J Endocrinol 2000; 166:111-20; PMID:10856889; http://dx.doi.org/10.1677/joe.0. 1660111.
133. Shivaswamy V, McClure M, Passer J, Frahm C, Ochsner L, Erickson J, et al. Hyperglycemia induced by tacrolimus and sirolimus is reversible in normal sprague-dawley rats. Endocrine 2010; 37:489-96; PMID:20960173; http://dx.doi.org/10.1007/s12020-010-9332-6.
134. Holloszy JO, Fontana L. Caloric restriction in humans. Exp Gerontol 2007; 42:709-12; PMID:17482403; http://dx.doi.org/10.1016/j.exger.2007.03.009.
135. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011; 54:2506-14; PMID:21656330; http://dx.doi.org/10.1007/s00125-011-2204-7.
136. Weiss EP, Racette SB, Villareal DT, Fontana L, Steger-May K, Schechtman KB, et al. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr 2006; 84:1033-42; PMID:17093155.
137. Fontana L, Meyer TE, Klein S, Holloszy JO. Longterm calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA 2004; 101:6659-63; PMID:15096581; http://dx.doi.org/10.1073/ pnas.0308291101.
138. Berrigan D, Perkins SN, Haines DC, Hursting SD. Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. Carcinogenesis 2002; 23:817-22; PMID:12016155; http://dx.doi.org/10.1093/carcin/ 23.5.817.
139. Colman RJ, Beasley TM, Allison DB, Weindruch R. Attenuation of sarcopenia by dietary restriction in rhesus monkeys. J Gerontol A Biol Sci Med Sci 2008; 63:556-9; PMID:18559628.
140. Lefevre M, Redman LM, Heilbronn LK, Smith JV, Martin CK, Rood JC, et al. Caloric restriction alone and with exercise improves CVD risk in healthy nonobese individuals. Atherosclerosis 2009; 203:206-13; PMID:18602635; http://dx.doi.org/10.1016/j.atherosclerosis.2008.05.036.
141. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 2003; 54:131-52; PMID:12525670; http://dx.doi.org/10. 1146/annurev.med.54.101601.152156.
142. Edman U, Garcia AM, Busuttil RA, Sorensen D, Lundell M, Kapahi P, et al. Lifespan extension by dietary restriction is not linked to protection against somatic DNA damage in Drosophila melanogaster. Aging Cell 2009; 8:331-8; PMID:19627272; http://dx.doi.org/10.1111/j.1474-9726.2009.00480.x.
143. Blagosklonny MV. Calorie restriction: Decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 2010; 9:683-8; PMID:20139716; http://dx.doi.org/10.4161/cc.9.4.10766.
144. Fontana L, Partridge L, Longo VD. Extending healthy lifespan - from yeast to humans. Science 2010; 328:321-6; PMID:20395504; http://dx.doi.org/10.1126/ science.1172539.
145. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 2010; 468:1100-4; PMID:21179166; http://dx.doi.org/10.1038/nature09584.
146. Poplawski MM, Mastaitis JW, Isoda F, Grosjean F, Zheng F, Mobbs CV. Reversal of diabetic nephropathy by a ketogenic diet. PLoS ONE 2011; 6:18604; PMID:21533091; http://dx.doi.org/10.1371/journal.pone.0018604.
147. Balietti M, Casoli T, Di Stefano G, Giorgetti B, Aicardi G, Fattoretti P. Ketogenic diets: an historical antiepileptic therapy with promising potentialities for the aging brain. Ageing Res Rev 2010; 9:273-9; PMID:20188215; http://dx.doi.org/10.1016/j.arr.2010.02.003.
148. Yancy WS Jr, Foy M, Chalecki AM, Vernon MC, Westman EC. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. Nutr Metab (Lond) 2005; 2:34; PMID:16318637; http://dx.doi.org/10.1186/1743-7075-2-34.
149. Blagosklonny MV. Paradoxes of aging. Cell Cycle 2007; 6:2997-3003; PMID:18156807; http://dx.doi.org/10.4161/cc.6.24.5124.